Travere Therapeutics, Inc. (TVTX)
55.88
-1.79
(-3.10%)
USD |
NASDAQ |
Oct 06, 15:48
Travere Therapeutics Price to Book Value : 214.60 for Oct. 6, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 05, 2026 | 221.48 |
| October 02, 2026 | 218.63 |
| October 01, 2026 | 218.33 |
| September 30, 2026 | 226.12 |
| September 29, 2026 | 230.38 |
| September 28, 2026 | 236.45 |
| September 25, 2026 | 228.27 |
| September 24, 2026 | 232.80 |
| September 23, 2026 | 229.77 |
| September 22, 2026 | 231.50 |
| September 21, 2026 | 241.41 |
| September 18, 2026 | 241.02 |
| September 17, 2026 | 248.63 |
| September 16, 2026 | 243.79 |
| September 15, 2026 | 240.06 |
| September 14, 2026 | 252.66 |
| September 11, 2026 | 254.12 |
| September 10, 2026 | 259.26 |
| September 09, 2026 | 254.31 |
| September 08, 2026 | 253.73 |
| September 04, 2026 | 250.70 |
| September 03, 2026 | 255.54 |
| September 02, 2026 | 258.19 |
| September 01, 2026 | 252.35 |
| August 31, 2026 | 254.54 |
| Date | Value |
|---|---|
| August 28, 2026 | 252.20 |
| August 27, 2026 | 259.30 |
| August 26, 2026 | 257.77 |
| August 25, 2026 | 257.34 |
| August 24, 2026 | 250.47 |
| August 21, 2026 | 252.35 |
| August 20, 2026 | 247.55 |
| August 19, 2026 | 253.31 |
| August 18, 2026 | 245.40 |
| August 17, 2026 | 243.98 |
| August 14, 2026 | 238.64 |
| August 13, 2026 | 235.92 |
| August 12, 2026 | 238.72 |
| August 11, 2026 | 231.23 |
| August 10, 2026 | 233.84 |
| August 07, 2026 | 235.49 |
| August 06, 2026 | 239.83 |
| August 05, 2026 | 241.02 |
| August 04, 2026 | 215.14 |
| August 03, 2026 | 211.14 |
| July 31, 2026 | 214.64 |
| July 30, 2026 | 219.98 |
| July 29, 2026 | 213.37 |
| July 28, 2026 | 214.72 |
| July 27, 2026 | 217.67 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| BioMarin Pharmaceutical, Inc. | 1.712 |
| TG Therapeutics, Inc. | 13.14 |
| Krystal Biotech, Inc. | 7.130 |
| RenovoRx, Inc. | 6.960 |
| Pelthos Therapeutics, Inc. | -- |
Price to Book Value Related Metrics
| PS Ratio | 8.936 |
| Price to Free Cash Flow | 343.16 |
| Price | 55.88 |
| Earnings Yield | -1.37% |
| Market Cap | 5.262B |